UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
May 7, 1996
-----------------------------------
(Date of earliest event reported)
Cephalon, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-19119 23-2484489
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) ID No.)
145 Brandywine Parkway
West Chester, Pennsylvania 19380
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(215) 344-0200
--------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
--------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
ITEM 5. OTHER EVENTS.
On May 7, 1996, Cephalon and its partner, Chiron Corporation, announced
that the U.S. Food and Drug Administration (FDA) has scheduled Myotrophin
(rhIGF-1) for review by the FDA's Peripheral and Central Nervous System Drugs
Advisory Committee on June 7, 1996.
The companies plan to present findings from two completed clinical studies
which evaluated Myotrophins utility in treating amyotrophic lateral sclerosis
(ALS, or Lou Gehrig's disease). Data from these studies have been submitted to
the FDA in support of a Treatment Investigational New Drug application. The
companies plan to submit a New Drug Application (NDA) based upon these studies
later this year for clearance to market the drug in the United States.
This announcement contains forward-looking statements that involve risks
and uncertainties. A full discussion of the companies' operations and financial
condition, including factors that may affect future operating results, is
contained in documents the companies file with the SEC, such as form 10-Q and
10-K reports. These documents identify important factors that could cause the
companies' actual performance to differ from our current expectations.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements of Business Acquired: None
(b) Pro Forma Financial Information: None
(c) Exhibits: Reference is made to the Exhibit Index annexed hereto and
made a part hereof.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CEPHALON, INC.
Date: May 7, 1996 By:/s/ Bruce A. Peacock
-------------------------------------
Bruce A. Peacock
Executive Vice President and
Chief Operating Officer
EXHIBIT INDEX
-------------
EXHIBIT PAGE
- ------- ----
99.1 Press Release dated May 7, 1996. 5